Bid on Einstein Paper Stirs Concern

Push Up Prices Very few ";first quality" manuscripts-meaning seminal works on a subject familiar to the public, such as Newton's Principia-ever appear on the market, said Dillon, a specialist in historic scientific and medical books. They tend instead to be housed in institutions, as Principia has been for the last 250 years at a Cambridge University library. But the record price does focus interest on scientific manuscripts, Dillon said, and plenty of Einstein manuscripts of moderate importan

Written byNaomi Freundlich
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Very few ";first quality" manuscripts-meaning seminal works on a subject familiar to the public, such as Newton's Principia-ever appear on the market, said Dillon, a specialist in historic scientific and medical books. They tend instead to be housed in institutions, as Principia has been for the last 250 years at a Cambridge University library. But the record price does focus interest on scientific manuscripts, Dillon said, and plenty of Einstein manuscripts of moderate importance are in private hands.

"I would think it will draw upwards the price of Einstein manuscripts, and I'm not excluding others as well," he predicted. "I would expect an Isaac Newton manuscript to do somewhat better after the Einstein sale than before."

The manuscript was considered to be the most complete account of Einstein's special theory of relativity. Although this was not the first manuscript Einstein wrote on relativity-that one was written between 1905 and 1906-it ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies